Pharmacokinetic/Pharmacodynamic Modeling of GLP-1 in Healthy Rats
- 17 December 2011
- journal article
- research article
- Published by Springer Nature in Pharmaceutical Research
- Vol. 29 (4) , 1078-1086
Abstract
Purpose To provide a mechanism-based model to quantitatively describe GLP-1 pharmacokinetics (PK) and pharmacodynamics (PD) in rats. Methods Intravenous (IV), infusion (IF), subcutaneous (SC), and intraperitoneal (IP) doses of GLP-1 were administered after glucose challenge in healthy Sprague–Dawley rats. Blood was analyzed for GLP-1, glucose, and insulin. The PK-PD modeling was performed with ADAPT 5. The concentration-response curve was generated and analyzed in comparison with other incretin-related therapeutics. Results The PK of GLP-1 was described using a two-compartment model with a zero-order input accounting for endogenous GLP-1 synthesis. For SC and IP dosing, sequential zero-order and first-order absorption models reasonably described the rapid absorption process and flip-flop kinetics. In dynamics, GLP-1 showed insulinotropic effects (3-fold increase) after IV glucose challenge in a dose-dependent manner. The concentration-response curve was bell-shaped, which was captured using a biphasic two-binding site Adair model. Receptor binding of GLP-1 exhibited high capacity and low affinity kinetics for both binding sites (KD = 9.94 × 103 pM, K2 = 1.56 × 10−4 pM−1). Conclusions The PK of GLP-1 was linear and bi-exponential and its PD showed glucose-dependent insulinotropic effects. All profiles were captured by the present mechanistic model and the dynamic analysis yields several implications for incretin-related therapies.Keywords
This publication has 38 references indexed in Scilit:
- Effects of increasing doses of glucagon-like peptide-1 on insulin-releasing phases during intravenous glucose administration in miceAmerican Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 2011
- Pharmacokinetic and Pharmacodynamic Modeling of Exendin-4 in Type 2 Diabetic Goto-Kakizaki RatsThe Journal of Pharmacology and Experimental Therapeutics, 2011
- Allosteric Ligands of the Glucagon-Like Peptide 1 Receptor (GLP-1R) Differentially Modulate Endogenous and Exogenous Peptide Responses in a Pathway-Selective Manner: Implications for Drug ScreeningMolecular Pharmacology, 2010
- Effect of Endogenous GLP-1 on Insulin Secretion in Type 2 DiabetesDiabetes, 2010
- Peptide binding at the GLP-1 receptorBiochemical Society Transactions, 2007
- Small-molecule agonists for the glucagon-like peptide 1 receptorProceedings of the National Academy of Sciences, 2007
- Pharmacokinetics and Pharmacodynamics of Vildagliptin??in??Patients?? with Type??2??Diabetes??MellitusClinical Pharmacokinetics, 2007
- Pharmacokinetic and Pharmacodynamic Modeling of Recombinant Human Erythropoietin after Intravenous and Subcutaneous Administration in RatsThe Journal of Pharmacology and Experimental Therapeutics, 2006
- Pharmacokinetic actions of exendin‐4 in the rat: Comparison with glucagon‐like peptide‐1Drug Development Research, 2001
- Glucose tolerance and insulin action in rats with renovascular hypertension.Hypertension, 1991